Anti-topoisomerase I (Anti-Scl-70) antibodies in patients with systemic lupus erythematosus

Gussin, Hélène A.; Ignat, Georghe P.; Varga, John; Teodorescu, Marius

doi:10.1002/1529-0131(200102)44:2<376::aid-anr56>3.0.co;2-2

Cited by 66 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-topo I antibodies are positive in 1% to 3% of SLE patients, even by reliable methods such as immunodiffusion [8]. This may be explained by SLE-SSc overlap syndrome, not typical pure SLE [10,27], as shown in the present study.…”

Section: Discussionsupporting

confidence: 50%

“…When we tested 46 SLE sera (from Louisiana, not included in the present study) by a commercial anti-topo I ELISA, 41% were positive; however, only two of 19 were IP positive [10]. In the study that had 32 (25%) of 128 prevalence of anti-topo I in SLE [8], only four of 32 ELISA positives were double immunodiffusion positive, and data supporting the specificity of ELISA were limited. Some also reported 13% to 29% prevalence of anti-topo I in SLE [6,7,9,25] whereas others reported low prevalence by ELISA [5,11].…”

Section: Discussionmentioning

confidence: 99%

“…Reports on high prevalence of anti-topo I in SLE by ELISA and its association with SLE activity and nephritis [8,9] challenged the general observation on SSc specificity of anti-topo I and triggered much confusion and many controversies [5,10,11]. When we tested 46 SLE sera (from Louisiana, not included in the present study) by a commercial anti-topo I ELISA, 41% were positive; however, only two of 19 were IP positive [10].…”

Section: Discussionmentioning

confidence: 99%

“…Thus, the prevalence of anti-topo I in SLE appears to depend on the source of antigens or ELISA kits. In some studies [8-10], anti-topo I ELISA positives in SLE are detecting antibodies that are different from those detected by immunodiffusion and IP. False positives caused by anti-dsDNA/chromatin antibodies in SLE sera in ELISA for autoantibodies to DNA-binding proteins, such as Ku and replication protein A, are well documented [10,26].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study

Satoh

Krzyszczak

et al. 2011

Arthritis Res Ther

View full text Add to dashboard Cite

IntroductionThe presence of anti-topoisomerase I (topo I) antibodies is a classic scleroderma (SSc) marker presumably associated with a unique clinical subset. Here the clinical association of anti-topo I was reevaluated in unselected patients seen in a rheumatology clinic setting.MethodsSera from the initial visit in a cohort of unselected rheumatology clinic patients (n = 1,966, including 434 systemic lupus erythematosus (SLE), 119 SSc, 85 polymyositis/dermatomyositis (PM/DM)) were screened by radioimmunoprecipitation. Anti-topo I-positive sera were also tested with immunofluorescence and RNA immunoprecipitation.ResultsTwenty-five (15 Caucasian, eight African American, two Latin) anti-topo I positive patients were identified, and all except one met the ACR SSc criteria. Coexistence of other SSc autoantibodies was not observed, except for anti-U1RNP in six cases. When anti-topo I alone versus anti-topo I + U1RNP groups were compared, African American (21% vs. 67%), overlap with SLE (0 vs. 50%; P = 0.009) or PM/DM (0 vs. 33%; P = 0.05) or elevated creatine phosphokinase (CPK) (P = 0.07) were more common in the latter group. In comparison of anti-topo I-positive Caucasians versus African Americans, the latter more frequently had anti-U1RNP (13% vs. 50%), mild/no skin changes (14% vs. 63%; P = 0.03) and overlap with SLE (0 vs. 38%; P = 0.03) and PM/DM (0 vs. 25%; P = 0.05).ConclusionsAnti-topo I detected by immunoprecipitation in unselected rheumatology patients is highly specific for SSc. Anti-topo I coexisting with anti-U1RNP in African American patients is associated with a subset of SLE overlapping with SSc and PM/DM but without apparent sclerodermatous changes.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study

Satoh

Krzyszczak

et al. 2011

Arthritis Res Ther

View full text Add to dashboard Cite

show abstract

“…ATA is highly specific for SSc (90–100%), and is associated with diffuse cutaneous SSc (although still observed in limited forms), poor prognosis, and higher risk of pulmonary fibrosis [54,55,56]. Sensitivity and specificity for predicting radiographic ILD in SSc is approximately 45% and 81% respectively [57].…”

Section: Ctd Associated Autoantibodiesmentioning

confidence: 99%

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Jee

Adelstein

Bleasel

et al. 2017

JCM

View full text Add to dashboard Cite

The diagnosis of interstitial lung disease (ILD) requires meticulous evaluation for an underlying connective tissue disease (CTD), with major implications for prognosis and management. CTD associated ILD (CTD-ILD) occurs most commonly in the context of an established CTD, but can be the first and/or only manifestation of an occult CTD or occur in patients who have features suggestive of an autoimmune process, but not meeting diagnostic criteria for a defined CTD—recently defined as “interstitial pneumonia with autoimmune features” (IPAF). The detection of specific autoantibodies serves a critical role in the diagnosis of CTD-ILD, but there remains a lack of data to guide clinical practice including which autoantibodies should be tested on initial assessment and when or in whom serial testing should be performed. The implications of detecting autoantibodies in patients with IPAF on disease behaviour and management remain unknown. The evaluation of CTD-ILD is challenging due to the heterogeneity of presentations and types of CTD and ILD that may be encountered, and thus it is imperative that immunologic tests are interpreted in conjunction with a detailed rheumatologic history and examination and multidisciplinary collaboration between respiratory physicians, rheumatologists, immunologists, radiologists and pathologists.

show abstract

Topotecan and the development of scleroderma or a scleroderma‐like illness

Ene-Stroescu¹,

Ellman²,

Peterson³

2002

Arthritis & Rheumatism

View full text Add to dashboard Cite

Enthesitis is a cardinal feature of spondylarthropathy (SpA) (1). One of the most challenging issues in the treatment of SpA concerns refractory heel pain caused by Achilles enthesopathy, retrocalcaneal bursitis, and plantar fasciitis (2). Early reports suggest that the anti-tumor necrosis factor ␣ monoclonal antibody, infliximab, is very efficacious in patients with severe SpA (3,4). We now report our experience with 2 HLA-B27-positive SpA patients who had refractory erosive calcaneal enthesitis without any other articular or axial symptoms, and who experienced significant remission, documented by ultrasonography, following initiation of treatment with infliximab.Both patients received a 3-mg/kg infusion of infliximab at weeks 0, 2, and 6, which was well tolerated. Control examinations were subsequently performed at weeks 10 and 14. At each visit, heel pain was measured on a visual analog scale (VAS), clinical and ultrasound examinations were performed by independent examiners, and the serum level of C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) were determined. Ultrasound examination was performed with real-time high-resolution equipment (AU5 Harmonic; Esaote, Genova, Italy) using a 13-MHz linear array transducer. Inflammatory activity was evaluated using the power Doppler mode at the following settings: medium flow optimum, low wall filter, dynamic range 50 dB, pulse repetition frequency 750 Hz.The first patient, a 21-year-old man, presented with a 10-year history of inflammatory right heel pain and a 3-year history of left heel pain, corresponding with radiographically evident erosions of both calcanei. Prior treatments had included nonsteroidal antiinflammatory drugs (NSAIDs), sulfasalazine (SSZ) for 2 years, multiple local injections of corticosteroids, local radiotherapy, and even local surgery, all of which proved unsuccessful. The patient had stopped working as a baker because of the disabling heel pain. The level of pain on a 100-point VAS was 76 for the right heel and 56 for the left heel. Physical examination at baseline revealed bilateral painful and tender heels at the insertion of the Achilles tendon and plantaris fascia. Magnetic resonance imaging showed bilateral edema and erosions of the entheseal portion of the calcaneus, inflammatory aspects of the Achilles tendon and plantaris fascia. Ultrasound examination revealed bilateral hypoechoic thickening of the Achilles tendon at the entheses, with calcific deposits and bone cortex erosion of the calcaneus ( Figure 1A). Power Doppler sonography showed increased blood flow from the periosteal bone to the entheses of the Achilles tendon and plantaris fascia, predominantly in the left side ( Figure 1A).Partial clinical improvement was noticeable as early as week 2 after the initiation of infliximab treatment (heel pain [for each heel] scored 33 on a 100-point VAS), and complete clinical remission (heel pain scored 0; negative physical findings) was achieved after the second infusion of infliximab (week 6) and was maintained at ...

show abstract

Anti-topoisomerase I (Anti-Scl-70) antibodies in patients with systemic lupus erythematosus

Cited by 66 publications

References 24 publications

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Topotecan and the development of scleroderma or a scleroderma‐like illness

Contact Info

Product

Resources

About